Premium
Serum enolase: a non‐destructive biomarker of white skeletal myopathy during pancreas disease ( PD ) in A tlantic salmon S almo salar L.
Author(s) -
Braceland M,
McLoughlin M F,
Tinsley J,
Wallace C,
Cockerill D,
McLaughlin M,
Eckersall P D
Publication year - 2015
Publication title -
journal of fish diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.819
H-Index - 85
eISSN - 1365-2761
pISSN - 0140-7775
DOI - 10.1111/jfd.12296
Subject(s) - salmo , biomarker , biology , myopathy , enolase , western blot , pancreas , immunohistochemistry , pathology , skeletal muscle , endocrinology , fishery , fish <actinopterygii> , immunology , medicine , biochemistry , genetics , gene
Diseases which cause skeletal muscle myopathy are some of the most economically damaging diseases in Atlantic salmon, S almo salar L., aquaculture. Despite this, there are limited means of assessing fish health non‐destructively. Previous investigation of the serum proteome of Atlantic salmon, S almo salar L., during pancreas disease ( PD ) has identified proteins in serum that have potential as biomarkers of the disease. Amongst these proteins, the enzyme enolase was selected as the most viable for use as a biomarker of muscle myopathy associated with PD . Western blot and immunoassay ( ELISA ) validated enolase as a biomarker for PD , whilst immunohistochemistry identified white muscle as the source of enolase. Enolase was shown to be a specific marker for white muscle myopathy in salmon, rising in serum concentration significantly correlating with pathological damage to the tissue.